SPDR S&P Pharmaceuticals ETF Rating $44.71 -0.22 (-0.49%) As of 02/21/2025 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings SPDR S&P Pharmaceuticals ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XPH Aggregate RatingModerate Buy 2.73Holdings in XPH have an aggregate rating of Moderate Buy based on 385 analyst ratings issued in the past year covering 45 companies (99.9% of the portfolio).XPH Aggregate Price Target$44.71High Prediction$44.71Average Prediction$44.71Low Prediction$44.71Holdings in XPH have an aggregate price target of $44.71 and a range of $44.71 to $44.71 covering 45 companies (99.9% of the portfolio).XPH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy20 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 45 XPH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.30%ITCIIntra-Cellular Therapies$128.60+0.0%3.8947 of 5 stars2.53$103.62 -19.4%15Earnings ReportAnalyst ForecastNews Coverage4.34%RPRXRoyalty Pharma$33.42+0.3%4.5708 of 5 stars3.00$41.60 24.5%6Positive News4.04%AXSMAxsome Therapeutics$137.75+6.7%4.5296 of 5 stars3.00$157.64 14.4%15Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage3.90%CORTCorcept Therapeutics$63.54-2.4%4.7297 of 5 stars3.00$88.25 38.9%5Upcoming Earnings3.66%TARSTarsus Pharmaceuticals$47.84-1.8%1.1673 of 5 stars3.00$56.00 17.1%7Gap Up3.66%JNJJohnson & Johnson$162.35+1.7%4.5449 of 5 stars2.56$170.67 5.1%18Ex-DividendAnalyst ForecastOptions VolumePositive News3.65%BMYBristol-Myers Squibb$55.85+0.1%4.5925 of 5 stars2.30$57.86 3.6%20Analyst RevisionPositive News3.63%LLYEli Lilly and Company$874.12+0.1%4.8481 of 5 stars2.85$1,007.94 15.3%20Positive News3.59%PFEPfizer$26.32+1.6%4.9993 of 5 stars2.50$31.92 21.3%16Options VolumePositive News3.53%JAZZJazz Pharmaceuticals$136.01-0.5%4.9569 of 5 stars2.93$180.33 32.6%15Upcoming EarningsNews Coverage3.47%EWTXEdgewise Therapeutics$27.07-0.1%1.6533 of 5 stars2.86$41.29 52.5%73.40%ZTSZoetis$160.39+1.9%4.8729 of 5 stars3.08$214.90 34.0%12Positive News3.34%OGNOrganon & Co.$15.47-1.4%4.9284 of 5 stars2.43$20.80 34.5%73.22%PRGOPerrigo$25.37+0.5%4.9671 of 5 stars2.40$35.00 38.0%5Dividend IncreaseAnalyst DowngradeNews Coverage3.22%ELANElanco Animal Health$11.02-1.0%4.051 of 5 stars2.25$16.00 45.2%8Analyst Forecast3.18%MRKMerck & Co., Inc.$89.40+2.0%5 of 5 stars2.58$116.39 30.2%24Analyst DowngradeOptions Volume3.12%HRMYHarmony Biosciences$34.56-0.9%4.731 of 5 stars3.00$53.67 55.3%9Analyst ForecastAnalyst RevisionNews Coverage2.99%VTRSViatris$11.25+1.7%2.3267 of 5 stars2.00$13.67 21.5%3News Coverage2.45%HROWHarrow$28.95-3.9%2.2885 of 5 stars3.00$61.50 112.4%42.39%PBHPrestige Consumer Healthcare$84.66-0.1%4.1695 of 5 stars2.60$92.60 9.4%5Positive News2.12%PCRXPacira BioSciences$25.16-2.3%2.9696 of 5 stars2.22$22.78 -9.5%92.11%COLLCollegium Pharmaceutical$29.13-2.1%3.9883 of 5 stars2.80$43.60 49.7%5News Coverage2.09%ANIPANI Pharmaceuticals$57.94-2.9%4.3784 of 5 stars3.00$77.71 34.1%81.77%LQDALiquidia$16.11-2.4%2.0541 of 5 stars3.11$25.38 57.5%91.71%AMPHAmphastar Pharmaceuticals$31.28-0.1%4.4394 of 5 stars2.25$50.33 60.9%41.69%ARVNArvinas$17.77-3.3%3.0809 of 5 stars3.00$60.00 237.6%12Gap Up1.65%SUPNSupernus Pharmaceuticals$33.05-4.5%1.6129 of 5 stars2.33$36.00 8.9%3Analyst DowngradeNews Coverage1.54%CRMDCorMedix$10.13-6.4%1.3225 of 5 stars3.00$15.67 54.7%6News CoveragePositive News1.46%LGNDLigand Pharmaceuticals$120.56-1.2%4.1424 of 5 stars3.00$147.00 21.9%6Positive News1.44%WVEWave Life Sciences$11.13-1.8%4.3752 of 5 stars3.00$22.22 99.7%9Positive NewsGap Up1.34%EOLSEvolus$13.99-4.3%3.8684 of 5 stars3.00$23.67 69.2%41.27%INVAInnoviva$18.08+0.1%2.7143 of 5 stars3.001Analyst DowngradeNews CoveragePositive News1.24%AMRXAmneal Pharmaceuticals$7.83-0.5%3.7675 of 5 stars2.80$10.00 27.7%5Positive News1.17%OCULOcular Therapeutix$7.00-3.4%3.3993 of 5 stars2.83$17.00 142.9%60.83%EYPTEyePoint Pharmaceuticals$6.15-3.1%1.3645 of 5 stars3.00$26.63 332.9%9Positive News0.78%ZVRAZevra Therapeutics$7.68-1.9%1.8488 of 5 stars3.25$21.57 180.9%80.78%ELVNEnliven Therapeutics$21.80+1.5%1.8116 of 5 stars3.20$38.25 75.5%50.76%MNMDMind Medicine (MindMed)$7.63-6.7%2.1419 of 5 stars3.23$26.33 245.1%13Gap Up0.69%ESPREsperion Therapeutics$1.83-1.4%4.4382 of 5 stars2.50$6.75 269.9%6Gap Down0.66%PHATPhathom Pharmaceuticals$5.67+2.3%2.1726 of 5 stars2.80$23.00 305.6%50.64%XERSXeris Biopharma$3.75-5.5%3.7339 of 5 stars2.75$5.15 37.3%4News Coverage0.58%NUVBNuvation Bio$2.21-2.9%2.0453 of 5 stars3.00$8.20 271.9%50.58%PLRXPliant Therapeutics$3.08+2.3%4.5774 of 5 stars2.45$17.75 476.3%110.55%PAHCPhibro Animal Health$22.50-2.0%4.079 of 5 stars1.50$21.00 -6.7%4Analyst Revision0.33%NMRANeumora Therapeutics$1.80+5.3%4.074 of 5 stars2.71$16.50 816.7%7News Coverage This page (NYSEARCA:XPH) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XPH Stock Alerts